Endonovo Therapeutics Bundle
What is Endonovo Therapeutics' History?
Endonovo Therapeutics is a biotech firm focused on non-invasive treatments. Its key innovation, SofPulse®, gained FDA clearance in December 2008 for pain and post-surgical edema relief.
Founded in 2008, the company aimed to develop wearable devices using bioelectricity for healing. As of July 2025, its market cap is around $110,000 with 1.1 billion shares.
The company's journey includes developing its proprietary non-contact electromagnetic field device, SofPulse®, which is designed to reduce pain and inflammation. This technology aims to enhance microcirculation and tissue repair for various conditions, aligning with the growing digital health market, which is projected to reach $7 trillion by 2025. The company's strategic initiatives are geared towards leveraging this expanding market. The Endonovo Therapeutics BCG Matrix outlines potential growth areas.
What is the Endonovo Therapeutics Founding Story?
Endonovo Therapeutics, Inc. was established in 2008 with its headquarters in Los Angeles, California. The company's founding mission was to pioneer non-invasive medical devices employing Electroceutical™ Therapy to address inflammatory conditions, cardiovascular diseases, and central nervous system disorders.
The Genesis of Endonovo Therapeutics
Founded in 2008, Endonovo Therapeutics embarked on a mission to revolutionize medical treatment through bioelectricity. The company's vision was to create wearable, non-invasive devices that leverage the body's natural healing processes.
- Endonovo Therapeutics company was founded in 2008.
- The company's core technology is Electroceutical™ Therapy.
- The initial focus was on inflammatory conditions, cardiovascular diseases, and CNS disorders.
- The goal was to restore electrochemical processes for healing.
The leadership of Endonovo Therapeutics, Inc. is anchored by Alan Collier, serving as Chairman and Chief Executive Officer, who brings over two decades of diverse experience in corporate finance, intellectual property, telecommunications, and technology, with a recent emphasis on healthcare. Ira Weisberg, as President and Chief Commercial Officer of the medical division, contributes more than thirty years of expertise in healthcare and pharmaceutical management, business development, and corporate finance. This blend of financial acumen and healthcare industry experience has been pivotal in guiding the company's strategic trajectory.
The primary challenge identified by Endonovo Therapeutics was the demand for non-pharmacological solutions for pain and inflammation management, alongside tissue repair. This led to the development of the SofPulse® device, which utilizes targeted pulsed electromagnetic field (tPEMF) technology. The SofPulse® device was engineered to alleviate pain, reduce inflammation and edema, and improve microcirculation and tissue repair. The company's initial business strategy involved technology licensing and commercialization, concentrating on its proprietary square waveform device. The Endonovo Therapeutics history includes significant regulatory milestones; the Electroceutical™ Therapy received FDA clearance in December 2008 for the palliative treatment of pain and post-surgical edema, and a CE Mark for wound healing. While specific initial funding details are not widely publicized, the company has secured an undisclosed amount through nine funding rounds, commencing with its first round in August 2014 and its most recent Post IPO round in May 2020. Understanding the Target Market of Endonovo Therapeutics is crucial to appreciating its strategic development.
Endonovo Therapeutics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Endonovo Therapeutics?
The early growth of Endonovo Therapeutics was centered on its innovative SofPulse® device, a non-invasive product utilizing targeted pulsed electromagnetic field (tPEMF) technology. This device received FDA clearance in December 2008 for pain and post-surgical edema, and a CE Mark for wound healing, establishing it as a non-pharmacological treatment option. The company's expansion efforts included strategic distribution agreements, such as the one in January 2023 with Pulse Therapeutics to distribute SofPulse® in Mexico and Costa Rica, following an initial order of $300,000.
Early Product Development and FDA Clearance
Endonovo Therapeutics' initial focus was the development and commercialization of SofPulse®, a device employing targeted pulsed electromagnetic field (tPEMF) technology. This product achieved FDA clearance in December 2008 for pain and post-surgical edema, and a CE Mark for wound healing, marking a significant milestone in its early product development.
Geographical Market Expansion Initiatives
To broaden its market presence, Endonovo Therapeutics engaged in strategic distribution initiatives. An example is the non-exclusive distribution agreement signed in January 2023 with Pulse Therapeutics for Mexico and Costa Rica, which included an initial order of $300,000, demonstrating the company's commitment to expanding its international reach.
Strategic Spin-off of Medical Device Assets
In a significant strategic move in December 2022, Endonovo Therapeutics announced plans to spin off its medical device assets, including SofPulse®, into a new entity named SofPulse, Inc. This transaction was finalized in March 2024 for a minimum of $50 million, allowing Endonovo to concentrate on non-medical human PEMF intellectual property and wellness markets.
Focus on Digital Health and Wellness Markets
Endonovo Therapeutics is exploring the creation of an online marketplace for wellness and medical products, aligning with the e-health market's projected growth to $660 billion by 2025. The company's market capitalization was approximately $110,000 as of July 2025, with trailing 12-month revenue reported at $1.66K as of March 31, 2025, reflecting a pivot towards digital health opportunities. This strategic shift is detailed further in the Marketing Strategy of Endonovo Therapeutics.
Endonovo Therapeutics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Endonovo Therapeutics history?
The history of Endonovo Therapeutics is marked by significant advancements in non-invasive electroceutical therapies and a strategic pivot to optimize its market position. The company's journey reflects a commitment to innovation in bioelectronic medicine, alongside navigating financial realities and market dynamics. This Endonovo Therapeutics company background highlights its key developments and the challenges it has faced.
| Year | Milestone |
|---|---|
| 2008 | Received FDA clearance for its SofPulse® device for pain and post-surgical edema treatment. |
| 2015 | Filed a patent application for a cell therapy using cord blood and tissue-derived cells, the first product from its Cytotronics™ platform. |
| 2017 | Filed a non-provisional patent application for a method to treat tissues and organs using its non-invasive electroceutical technology. |
| 2024 | Finalized an asset purchase agreement for its medical device assets, including SofPulse®, for a minimum of $50 million. |
Endonovo Therapeutics has pioneered innovations in bioelectronic medicine, notably with its proprietary Electroceutical™ Therapy. The company's Cytotronics™ platform represents a significant advancement, focusing on manipulating cells with time-varying electromagnetic fields for tissue engineering and cell therapies. This platform aims to create enhanced stem cells and off-the-shelf therapeutic products, showcasing the company's dedication to developing novel treatments.
Electroceutical™ Therapy
This core technology focuses on non-invasive treatments utilizing electrical stimulation for therapeutic purposes.
SofPulse® Device
Received FDA clearance in 2008 for pain and edema, and CE Mark approval for wound healing, establishing its commercial viability.
Cytotronics™ Platform
This platform aims to expand and manipulate cells using electromagnetic fields for advanced cell therapies and tissue engineering.
Cell Therapy Patent
A patent application filed in 2015 for a cell therapy derived from cord blood and tissue cells, marking a key development for the Cytotronics™ platform.
Intellectual Property Portfolio
The company holds numerous patents and trademarks, underscoring its commitment to innovation and protecting its proprietary technologies.
Non-Invasive Therapeutic Methods
Ongoing research and patent filings for new methods to treat tissues and organs using its non-invasive electroceutical technology.
Endonovo Therapeutics has faced significant financial challenges, with a trailing 12-month revenue of $1.66K and a net income of ($2,621K) as of March 31, 2025. The company's stock price has experienced a downward trend since November 2012, with projections indicating a further decrease. These financial realities necessitated a strategic restructuring, including the spin-off of its medical device assets to SofPulse, Inc. in March 2024 for a minimum of $50 million, as detailed in the Growth Strategy of Endonovo Therapeutics.
Financial Performance
Reported low revenue and significant net losses as of early 2025, indicating financial strain. Total debt stood at $6,870K.
Stock Value Decline
The company's stock has shown a consistent decline since late 2012, with forecasts suggesting continued downward pressure.
Strategic Spin-off
To address market dynamics and unlock value, the medical device division was spun off to SofPulse, Inc. in a deal finalized in March 2024.
Focus Shift
This pivot allows the core company to concentrate on non-medical human PEMF intellectual property and wellness markets, while enabling the spun-off entity to pursue its own growth.
Capitalization of New Entity
SofPulse, Inc. underwent a capital raise with a pre-money valuation of approximately $25.2 million in March 2024 to support its operational development.
Market Competitiveness
The restructuring aims to enhance the competitiveness, marketability, and financeability of both the legacy medical division and new ventures.
Endonovo Therapeutics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Endonovo Therapeutics?
The history of Endonovo Therapeutics company showcases a journey from medical device development to a strategic pivot towards digital health and wellness. Founded in 2008, the company achieved early milestones with FDA clearance for its SofPulse® device. Its development path includes securing patents for electromagnetic field therapies and exploring cell-based treatments, marking significant Endonovo Therapeutics milestones.
| Year | Key Event |
|---|---|
| 2008 | Endonovo Therapeutics, Inc. was founded in Los Angeles, California. |
| December 2008 | SofPulse® device received FDA clearance for pain and post-surgical edema. |
| July 2010 | Patent issued for an integrated coil apparatus for therapeutic treatment using electromagnetic fields. |
| February 2015 | Patent issued for devices and methods to treat degenerative joint diseases with electromagnetic fields. |
| October 2015 | Patent application filed for a cell therapy using cord blood and tissue-derived cells. |
| March 2017 | Non-provisional patent application filed for a method to treat tissues and organs using electroceutical technology. |
| July 2019 | Dr. Steven Levin joined the scientific advisory board to aid device introduction into hospitals and clinics. |
| December 2022 | Plans announced to spin off medical device assets, including SofPulse®, to a new company, SofPulse, Inc. |
| January 2023 | Non-exclusive distribution agreement signed with Pulse Therapeutics for SofPulse® devices in Mexico and Costa Rica, with an initial order of $300,000. |
| March 2024 | Asset Purchase Agreement finalized for the acquisition of Endonovo's assets and Intellectual Property by SofPulse, Inc. for a minimum of $50 million. |
| March 2024 | SofPulse, Inc. commenced a capital raise of up to $1,000,000 for accredited investors. |
| March 31, 2025 | Endonovo Therapeutics reported trailing 12-month revenue of $1.66K and a net loss of $2,621K. |
Strategic Shift to Digital Health
Endonovo Therapeutics is transitioning to an AI-driven digital health and wellness platform. This move aims to capitalize on the projected $7 trillion digital health market by 2025. The company plans to offer wellness and medical products through an online marketplace.
Leveraging Intellectual Property for Wellness Products
The company intends to develop new over-the-counter wellness products. These products will utilize its proprietary multi-coil intellectual property technology. This expansion broadens the application of its core innovation beyond traditional medical devices.
Analyst Predictions and Future Growth Drivers
Analyst predictions for Endonovo Therapeutics (ENDV) stock show varied outlooks, with some forecasting long-term positive trends. Potential price targets include an average of $0.0415 in 2025 and $0.0943 by 2030. However, other analyses suggest a downtrend, predicting a price of $0.000033 by July 2026.
Connecting Past Vision with Future Strategy
The company's forward-looking strategy aligns with its founding vision of using bioelectricity for healing. This vision is now being extended into broader wellness and digital health solutions. The successful execution of this shift and the performance of SofPulse, Inc. will be key to its future growth.
Endonovo Therapeutics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Endonovo Therapeutics Company?
- What is Growth Strategy and Future Prospects of Endonovo Therapeutics Company?
- How Does Endonovo Therapeutics Company Work?
- What is Sales and Marketing Strategy of Endonovo Therapeutics Company?
- What are Mission Vision & Core Values of Endonovo Therapeutics Company?
- Who Owns Endonovo Therapeutics Company?
- What is Customer Demographics and Target Market of Endonovo Therapeutics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.